Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+15.8%
3 months
+10.1%
6 months
+43.2%
1 year
+45.4%
Year to date
+26.6%
52-week range
$848.50 – $1,417.99
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$1.27T
P/E
46.2
P/B
31.6
P/S
14.7
Revenue
$86.46B
Net income
$27.58B
Diluted EPS
30.81
Gross margin
83.60%
Net margin
31.90%
Return on equity
83.60%
Total debt
$49.5B
Cash
$4.89B
Free cash flow
$19.66B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$24.4B
$6.45B
83.90%
26.40%
$8.22B
Jun 30, 2026
$22.97B
$7.1B
85.80%
30.90%
$7.76B
Mar 31, 2026
$19.8B
$7.4B
81.90%
37.40%
$3.01B
Dec 31, 2025
$19.29B
$6.64B
82.50%
34.40%
$677.9M
Sep 30, 2025
$17.6B
$5.58B
82.90%
31.70%
$6.75B
Jun 30, 2025
$15.56B
$5.66B
84.30%
36.40%
$1.39B
Mar 31, 2025
$12.73B
$2.76B
82.50%
21.70%
$156.1M
Dec 31, 2024
$13.53B
$4.41B
82.20%
32.60%
$977.8M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Charles River Laboratories International, Inc. reported solid Q3 2026 financial performance, with revenue and non-GAAP EPS exceeding prior guidance, driven by strong growth in the DSA and manufacturing segments. The company raised its full-year 2026 guidance, expecting continued mid-single-digit growth and significant operating margin expansion. Management expressed optimism about improving biopharmaceutical demand and the long-term tailwind of AI in drug development.
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025.Mike Blake | ReutersEli Lilly is slated to report third-quarter earnings and revenue on Thursday, which will likely...